Please provide your email address to receive an email when new articles are posted on . AGA guidance strongly recommends antiviral prophylaxis for patients at high risk for hepatitis B reactivation.

Schematic representation of histone-modifying factor recruitment on cccDNA minichromosomes in relation to viral protein HBx. In the presence of HBx, histone-modifying factors such as p300/CBP, Set1A, ...

PBGENE-HBV is designed to potentially cure chronic hepatitis B by eliminating the root cause of the virus. The Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-HBV, an ...

Jody Baron and Gabi Fragiadakis discover why some people with chronic Hepatitis B are cured after they're taken off of ...

Virion Therapeutics Reports Broad and Sustained Anti-HBV Immunity Following a Single VRON-0200 Dose in the Majority of Chronically HBV-Infected Patients From its Phase 1b Study at CROI 2026 Virion ...

On Wednesday, Precision BioSciences, Inc. (NASDAQ:DTIL) revealed initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ELIMINATE-B trial. The ...

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ...

The Wisconsin Department of Health Services (DHS) is announcing a plan to eliminate viral hepatitis and a public dashboard to ...

The patient had been living with Hepatitis B for several years and was diagnosed with HIV around three years ago. Over time, ...